Pakistan to purchase 1.2m coronavirus vaccine doses from Sinopharm

Gulf Today Report

As the death toll from coronavirus surpassed the 10,000 mark on Wednesday, Pakistan will purchase 1.2 million vaccine doses from China’s Sinopharm, a minister said on Thursday.

The first official confirmation of a vaccine purchase by the South Asian country as it battles a second wave of infections. The number of countries have pre-booked vaccines based on preliminary or incomplete results to ensure availability.

A health official in protective gear holds a sample collected from a man for COVID-19 in Peshawar. File/AP

A special cabinet committee decided to pre-book 1.2 million doses of vaccine from a Chinese state-owned company ‘Sinopharm’.

China approved a coronavirus vaccine developed by an affiliate of state-backed pharmaceutical giant Sinopharm on Thursday, its first approved shot for general public use.

Pakistani Minister for Science and Technology Chaudhry Fawad Hussain said on Twitter that “The Cabinet Committee has decided to initially purchase 1.2 million doses of the vaccine from the Chinese company Sinopharm, which will be provided free of cost to frontline workers in the first quarter of 2021.”

READ MORE

Nawaz Sharif’s passport will be cancelled on Feb.16, says Pakistani minister

Nurse tests positive for coronavirus after taking the vaccine

Pakistan had earlier this month approved $150 million in funding to buy COVID-19 vaccines, initially to cover the most vulnerable 5% of the population.

The country did not announce which vaccine it would procure, but said a panel of experts was compiling a list of recommendations and that it could tap more than one source.

“If the private sector wants to import any other internationally-approved vaccine, it can do so,” Hussain said on Thursday.

The country of 220 million is in the midst of another spate of infections, with 58 deaths on Wednesday taking its death toll past 10,000.

It also reported 2,475 new infections, taking the total to 479,715.

Pakistan is also running phase III clinical trials for CanSino Biologics’ COVID-19 vaccine candidate, Ad5-nCoV, led by the government-run National Institute of Health.